New pill aims to quiet heartburn without damaging the esophagus

NCT ID NCT07160790

Not yet recruiting Symptom relief Sponsor: Onconic Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called JP-1366 for people with non-erosive gastroesophageal reflux disease (NERD), a condition causing heartburn without visible damage to the esophagus. About 321 adults will take either JP-1366 or a placebo daily. The main goal is to see if the drug increases the number of days without heartburn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

JP-1366 (a drug for acid reflux)

What this could lead to

If it works, this could provide a new treatment option to reduce heartburn in people with non-erosive reflux disease.

What could go wrong

This is a Phase 3 trial, but results may not confirm benefit. Side effects are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease Non-Erosive Reflux Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE